Can-Fite Submits Application To FDA For Orphan Drug Designation For Its Drug Candidate Namodenoson In The Treatment Of Pancreatic Carcinoma

Can-Fite plans to start shortly a Phase IIa clinical study that will be a multicenter open-label trial in patients with advanced pancreatic adenocarcinoma whose disease has progressed on at least first line therapy. The trial will evaluate the safety, clinical activity, and pharmacokinetics (PK) of Namodenoson in this population. 

Can-Fite has already been granted Orphan Drug Status for Namodenoson for the indication of advanced liver cancer by the FDA and  also by the EMA.